Document:

Exhibit
10.40

 

EXHIBIT
G:

PLEDGOR
ROYALTY AGREEMENT AMENDED

NOVEMBER
13, 2019

 

This
is an amendment to that Royal Participation Agreement (the “Original Royalty Agreement “) made and effective on June
6, 2019, by and between NutraLife BioSciences, Inc., a Florida corporation (“NutraLife”), PhytoChem Technologies,
Inc. (“PhytoChem”), a Florida corporation (NutraLife and PhytoChem are collectively referred to herein as the “Company”),
Brenda Hamilton, an individual (the “Pledgor”) and Kahn Family Limited PT II (the “Purchaser”) and is
effective as of the day set forth on the signature page hereto. The Company, the Pledgor and the Purchaser are referred to herein
collectively as the “Parties”, or individually as a “Party”.

 

NOW
THEREFORE, the Parties hereby amend and replace the Original Royalty Agreement in its entirety and replace it with this agreement,
(the “Pledgor Royalty Agreement”) in exchange for good and valuable consideration the receipt of which is hereby acknowledged
as follows:

 

RECITALS

 

WHEREAS,
Company sold a Secured Convertible Promissory Note (the “Note”) to Kahn Family Limited PT I (“Purchaser”)
in a principal aggregate amount of $1,000,000 (the “Principal Amount”) pursuant to that certain Investment Agreement
(“Investment Agreement”), and entered into a Security agreement (the “Security Agreement”) of even date
herewith which is attached as Exhibit C to the Investment Agreement;

 

WHEREAS,
the first four of the Ennea Processors that the Company commercializes and/or monetizes pursuant to the Morgan Agreement shall
serve as collateral (“Collateral Processors”) for the Principal Amount pursuant to the terms of the Security Agreement
and Note attached to the Investment Agreement as Exhibit B;

 

WHEREAS,
in addition to the Collateral (as defined in the Note and Security Agreement) and consideration provided by the Company, the
Purchaser requested additional collateral (the “Additional Collateral”) in the form of real property as a condition
precedent to providing the Principal Amount of the Note to the Company;

 

WHEREAS,
the Company plans to use the Note proceeds to commercialize and monetize a phytoextractor (the “Ennea Processor”)
that uses certain technologies to separate and/or process the components of hemp to remove and/or modify, purify, dilute and extract
bioactive ingredients and/or remove unwanted substances to produce finished products for a variety of applications pursuant to
an agreement by and between the Company and Owen J. Morgan(“Morgan”) dated February 4, 2019 (the “Morgan Agreement”).

 

WHEREAS,
the Pledgor agreed to provide a mortgage lien covering certain real property (the “Real Property”) as set forth
in the mortgage (the “Mortgage”) and Pledge Agreement (“Pledge Agreement”) of even date herewith as the
Additional Collateral. In exchange for providing the Additional Collateral, among other things, the Company desires to pay to
the Pledgor the consideration set forth in the Pledge Agreement which includes a royalty (the “Royalty” or (the “Royalty
Payments”) of eight and one-half percent (8.5%) of Net Revenue (as defined herein) derived from the Collateral Processors
so long as any portion of the Principal Amount is outstanding and five percent (5%) thereafter on the first two (2) machines monetized
and/or commercialized pursuant to the Owen Agreement; and

 

    	 

    	 

    

 

WHEREAS,
Pledgor and the Company wish to define the terms and conditions of the Royalty Payments to Pledgor by entering into this Pledgor
Royalty Agreement.

 

THEREFORE,
in consideration of the mutual considerations herein, the receipt of which is mutually acknowledged, the parties hereto agree
as follows:

 

ARTICLE
1. RECITALS.

 

ARTICLE
1.1 The above recitals are true and correct and made a part hereof.

 

ARTICLE
2. DEFINITIONS.

 

ARTICLE
2.1 ARTICLE 2.1 The Investment Agreement, Note, Purchaser Royalty Agreement, Security Agreement, and the Mortgage are referred
to as the “Ancillary Agreements”. This Pledgor Royalty Agreement and the Ancillary Agreements shall be referred
to collectively as the “Transaction Documents”.

 

ARTICLE
3. PLEDGE.

 

ARTICLE
3.1 Pledgor has agreed to provide the Additional Collateral for the Note as set forth in the Pledge Agreement based upon the
representations and warranties of the Company and Purchaser as set forth in the Transaction Documents.

 

ARTICLE
4. SOURCE, AMOUNT, AND TIMING OF ROYALTY PAYMENTS.

 

ARTICLE
4.1 Commencing upon the fiscal quarter in which revenue is derived directly or indirectly from any of the Collateral Processors,
the Company shall pay to the Pledgor non-refundable Royalty Payments consisting of eight and one-half percent (8.5%) of all “Net
Revenue” received by the Company as a result of the commercialization and/or monetization of the Collateral Processors until
such time as the Principal Amount has been paid. At such time as the Principal Amount has been paid to the Purchaser, Pledgor
shall receive non-refundable Royalty Payments consisting of five percent (5%) of “Net Revenue” received by the Company
as a result of the commercialization and/or monetization of the first two Ennea Processors resulting from the Morgan Agreement.

 

For
the purposes of this Pledgor Royalty Agreement, “Net Revenue” shall mean the total Gross Receipts less direct and
indirect expenses of Gross Receipts. Gross Receipts shall mean revenue from tolling fees and processing fees, product sales, extraction
services, licenses, development, commercialization and/or other commercialization and monetization of the Collateral Processors
including the use, disposition, sale or rental of the Collateral Processors.

 

ARTICLE
4.2 For the avoidance of doubt, Net Revenue shall be calculated in accordance with GAAP. The Company hereby agrees to use
its commercial best efforts to maximize its Gross Revenue during the term of this Pledgor Royalty Agreement and in the event it
commercializes any other phytoextractors similar to the Collateral Processors, it will not commercialize or monetize such other
equipment until the maximum capacity of the Collateral Processors has been reached. “Gross Revenues” shall also include
all settlement amounts, payment, and damages received by Company which result from litigation or disputes related to or arising
from the sale, license, development, commercialization and/or other monetization of the Collateral Processors.

 

    	 

    	 

    

 

ARTICLE
4.3 The Royalty Payments shall be paid by the Company to the Pledgor within fifteen (15) days after the end of the quarter
in which the Company receives payment for any Net Revenue from the Collateral Processors.

 

ARTICLE
5. INFORMATION REQUIRED TO BE SUPPLIED WITH EACH PAYMENT.

 

ARTICLE
5.1 With each Royalty Payment, the Company shall supply to the Pledgor a detailed and satisfactory accounting and reconciliation
of how the Royalty Payment was calculated within 5 days of Pledgor’s request. The Company agrees to have an officer certify
each reconciliation and provide a reconciliation each calendar month during the term of this Pledgor Royalty Agreement regardless
of whether any Royalty Payment is due.

 

ARTICLE
6. TERM.

 

ARTICLE
6.1 This Pledgor Royalty Agreement shall continue for a period of ten (10) years.

 

ARTICLE
7. NO SALE OR ASSIGNMENT.

 

ARTICLE
7.1 During the term of this Pledgor Royalty Agreement, the Company may not (i) sell (other than ordinary course sales to customers),
assign, or otherwise transfer or encumber the Collateral Processors, (ii) assign or otherwise transfer or encumber this Pledgor
Royalty Agreement, or (iii) create an obligation whereby the Company is required to pay all or a portion of the revenue derived
from the Collateral Processors to any party in priority to the Pledgor without first obtaining the prior written consent of the
Pledgor.

 

ARTICLE
8. EXTRAORDINARY EVENT.

 

ARTICLE
8.1 The Company agrees not to enter into a merger, recapitalization, sale or change of control of the Company or sale transaction
involving all or substantially all of the Company’s equity or assets unless the acquiring or successor entity agrees in
writing to recognize the Pledgor’s rights under this Pledgor Royalty Agreement.

 

ARTICLE
9. NOTICES.

 

ARTICLE
9.1 Any notice required or permitted by this Pledgor Royalty Agreement shall be in writing and shall be deemed sufficient
upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile, or 48 hours after being
deposited in the U.S. mail as certified or registered mail with postage prepaid, if such notice is addressed to the party to be
notified at such party’s address or facsimile number as set forth on the signature page hereto or as subsequently modified
by written notice.

 

    	 

    	 

    

 

ARTICLE
10. APPLICABLE LAW, VENUE, JURISDICTION.

 

ARTICLE
10.1 GOVERNING LAW AND JURISDICTION. This Pledgor Royalty Agreement shall be governed by and construed in accordance with
the laws of the State of Florida without regard to principles of conflict law applicable to contracts made and to be performed
with such state. Each of the parties hereto accepts for itself to the jurisdiction of Palm Beach County Florida and irrevocably
consents to such jurisdiction in any proceedings, and waives any objection to venue laid therein. Any controversy or claim arising
out of or relating of this Pledgor Royalty Agreement shall be settled by binding arbitration administered by the American Arbitration
Association and judgment on the award entered in any court having jurisdiction. The arbitration proceedings shall be conducted
before a panel of three neutral arbitrators in Palm Beach County, Florida all of whom shall be members of the bar of the state
of Florida, actively engaged in the practice of law for at least ten (10) years. Either Party hereto may apply to the arbitrator
seeking injunctive relief until the arbitration award is rendered or the controversy otherwise resolved. Either Party may, without
waiving any remedy under this Pledgor Royalty Agreement, seek from any court having jurisdiction any interim or provisional relief
that is necessary to protect the rights or property of that party, pending the arbitral tribunal’s determination of the
merits of the controversy. Each party shall bear its own costs, expenses and attorney fees and an equal share of the arbitrators’
and administrative fees of arbitration. Except as may be required by law, neither a party nor an arbitrator may disclose the existence
content or results of any arbitration hereunder without the prior written consent of the Parties. All documents, testimony and
records shall be received, heard and maintained by the arbitrators in secrecy, available for the inspection only of the Parties
to this Royalty Agreement and their respective attorneys and their respective experts who shall agree in advance and in writing
to receive all such information confidentially and to maintain such information in secrecy until such information shall become
generally known. In consideration for and as a material condition of this Pledgor Royalty Agreement, each Party agrees that final
and binding arbitration is the exclusive means for resolving any claim or controversy arising out of or related to this Royalty
Agreement. This Pledgor Royalty Agreement is a waiver of all rights the Parties may have to a civil court action. Accordingly,
only an arbitrator, not a judge or jury, will decide the dispute, although the arbitrator has the authority to award any type
of relief that could otherwise be awarded by a judge or jury.

 

ARTICLE
10.2 JOINT AND SEVERAL OBLIGATIONS. All obligations of NutraLife
and PhytoChem under the Transaction Documents are joint and not several. All obligations of the Pledgor are several and not joint
under the Transaction Documents, and in no event shall the Pledger have any liability or obligation with respect to the acts or
omissions of the Company or any other party to this Agreement.

 

ARTICLE
10.3 FURTHER ASSURANCES. Upon Pledgor’s reasonable request, the Company and Purchaser shall, at the Company’s
sole cost and expense, execute and deliver all such further documents and instruments, and take all such further acts, necessary
to give full effect to this P Pledgor Royalty Agreement.

 

ARTICLE
10.4 ENTIRE AGREEMENT. The Transaction Documents including the Pledgor Royalty Agreement constitute the sole and entire agreement
of the Parties with respect to the subject matter contained herein and therein, and supersedes all prior and contemporaneous understandings,
agreements, representations and warranties, both written and oral, with respect to such subject matter.

 

ARTICLE
10.5 HEADINGS. The headings in this Agreement are for reference only and do not affect the interpretation of this Pledgor
Royalty Agreement.

 

ARTICLE
10.6 AMENDMENT AND MODIFICATION. No amendment to this Pledgor Royalty Agreement is effective unless it is in writing and signed
by each Party.

 

    	 

    	 

    

 

ARTICLE
10.7 WAIVER. No waiver under this Pledgor Royalty Agreement is effective unless it is in writing and signed by the Party waiving
its right. Any waiver authorized on one occasion is effective only in that instance and only for the purpose stated and does not
operate as a waiver on any future occasion. None of the following constitutes a waiver or estoppel of any right, remedy, power,
privilege or condition arising from this Pledgor Royalty Agreement: (a) any failure or delay in exercising any right, remedy,
power or privilege or in enforcing any condition under this Pledgor Royalty Agreement; or (b) any act, omission or course of dealing
between the Parties.

 

ARTICLE
10.8 WAIVER OF CONFLICTS. The Company acknowledges that the Pledgor, Brenda Hamilton and her law firm, Hamilton & Associates
Law Group, P.A has in the past performed, and may continue to perform, legal and/or consulting services for the Company in connection
with the Transaction Documents and the matters and transactions described in the Transaction Documents well as in matters unrelated
to the Transaction Documents. Accordingly, the Company hereby acknowledges that it has been advised by Brenda Hamilton & Hamilton
& Associates Law Group, P.A. to seek the advice of independent legal counsel in connection with the Transaction Documents
and transactions contemplated thereby including the Pledge Agreement, Mortgage and Pledgor Royalty Agreement in which Brenda Hamilton
is a party. Additionally, the Company and each acknowledge that they have had an opportunity to ask for information relevant to
this disclosure and has consulted with independent legal counsel or has had the opportunity to do so and gives its informed consent
to Brenda Hamilton & Hamilton & Associates Law Group, P.A. representation of and/or performance of services for the Company
in the connection with the Transaction Documents and transactions contemplated thereby.

 

ARTICLE
10.9 EQUITABLE REMEDIES. Each Party acknowledges and agrees that (a) a breach or threatened breach by such Party of
any of its obligations would give rise to irreparable harm to the other Party for which monetary damages would not be an adequate
remedy and (b) in the event of a breach or a threatened breach by such Party of any such obligations, the other Party shall,
in addition to any and all other rights and remedies that may be available to such Party at law, at equity or otherwise in respect
of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance
and any other relief that may be available from a court of competent jurisdiction, without any requirement to post a bond or other
security, and without any requirement to prove actual damages or that monetary damages will not afford an adequate remedy. Each
Party agrees that such Party will not oppose or otherwise challenge the appropriateness of equitable relief or the entry by a
court of competent jurisdiction of an order granting equitable relief, in either case, consistent with the terms of this Section.

 

ARTICLE
10.10 SEVERABILITY. If any provision of this Pledgor Royalty Agreement is invalid, illegal or unenforceable, the balance of
this Pledgor Royalty Agreement shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it
shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount
deemed interest due hereunder violates applicable laws governing usury, the applicable rate of interest due hereunder shall automatically
be lowered to equal the maximum permitted rate of interest. The Company covenants (to the extent that it may lawfully do so) that
it shall not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay,
extension or usury law or other law which would prohibit or forgive the Company from paying all or any portion of the principal
of or interest on the Note as contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect
the covenants or the performance of the Note, and the Company (to the extent it may lawfully do so) hereby expressly waives all
benefits or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the
execution of any power herein granted to the Pledgor.

 

    	 

    	 

    

 

ARTICLE
10.11 COUNTERPARTS. This Pledgor Royalty Agreement may be executed in counterparts, each of which is deemed an original, but
all of which together are deemed to be one and the same agreement. A signed copy of this Pledgor Royalty Agreement delivered by
facsimile, e-mail or other means of electronic transmission is deemed to have the same legal effect as delivery of an original
signed copy of this Pledgor Royalty Agreement.

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Pledgor Royalty Agreement November 13, 2019.

 

	NUTRALIFE
    BIOSCIENCES, INC.	 	 	 
	 	 	 	 	 
	By:	                          	 	By:
    	                                               
	 	Edgar
Ward, Chief Executive Officer	 	 	Brenda
    Hamilton, an individual
	 	 	 	 	 
	PHYTOCHEM
    TECHNOLOGIES, INC.	 	Address for Notice:
	 	 	 	 
	By:	 	 	1576
Fan Palm Road Boca Raton Fl 33432

	 	Edgar
    Ward, Chief Executive Officer	 	Phone: 561-416-8956
	 	 	 	Email:
    bhamilton@securitieslawyer101.com
	Address
    for Notice:	 	 	 
	 	 	 	 
	NutraLife
    Biosciences, Inc.	 	 	 
	Attn: Edgar Ward, Chief Executive Officer

                                                                     6601 Lyons Rd. L-6, Coconut Creek Fl 33432

                                                                     Telephone: 561-212-3816
	 	 	 
	Email:
    edgar@NutraFuels.comExhibit
10.41

 

		Nutritional,
    Wellness & CBD Products
	Development,
    Manufacturing & Distribution
	 
	6601
    Lyons Road, L-6 

    Coconut Creek, Fl 33073
	Company
    Website: www.nutralifebiosciences.com

    Telephone: 1-888-509-8901 OTC Markets OTCQB: NLBS

 

 

February
12th, 2020

 

CONFIDENTIAL

Convertible
Promissory Note

Attn:
Barbara Ludwig

Address:
22 Saint Marks Place,

Massapequa,
NY 11758

 

Re:
$35,000.00 Promissory Note

 

FOR
VALUE RECEIVED, the undersigned, (the “Maker”), hereby promises to pay to the order of Barbara Ludwig (“Payee”),
the principal sum of $35,000 pursuant to the terms and conditions set forth herein.

 

PAYMENT
OF PRINCIPAL The principal amount of this Promissory Note (the “Note shall be due and payable in one (1) lump sum payment
on May 15th, 2020.

 

	1.	EQUITY
    KICKER. Payee shall receive three hundred and fifty thousand (350,000) shares of the Company’s common stock as additional
    consideration.

 

	2.	CONVERSION
    RIGHTS.
	 	At
    the election of Payee, at any time prior to the Maturity Date, Payee shall have the right, to convert all of the then outstanding
    principal amount and any and all accrued and unpaid interest on this Note into the Maker’s Common Stock at a price of
    ten cents ($0.10 USD) per share.
	 	 
	 	Payee
    shall exercise its conversion rights by providing written notice of conversion (the “Conversion Notice”) duly
    executed and given by Payee to Maker’s Common Stock in accordance with the procedures set forth herein. In order to
    convert the outstanding principal and interest into shares of Maker’s stock, Payee shall send the Conversion Notice
    which shall state therein nature and amount to be converted and the name or names in which the certificate or certificates
    for shares of Maker’s stock are to be issued. Payee’s right to convert this note into Maker’s Common Stock
    will expire on the Maturity Date. In the event that Payee is converting the then outstanding principal amount and any and
    all accrued and unpaid interest of this Note, Payee shall surrender this Note upon issuance of the certificate(s) representing
    such shares in Maker. Maker shall issue and deliver to Payee, or to the nominee or nominees of Payee, a certificate or certificates
    for the number of shares of Maker’s stock to which Payee shall be entitled as aforesaid. Such conversion shall be deemed
    to have been made on the close of business on the date of the Conversion Notice.

 

	4.	PREPAYMENT.
    The Maker shall have the right at any time and from time to time to prepay this Note in whole or in part without premium
    or penalty.

 

    	 

    	 

    

 

	5.	REMEDIES.
    No delay or omission on part of the holder of this Note in exercising any right hereunder shall operate as a waiver of
    any such right or of any other right of such holder, nor shall any delay, omission or waiver on any one occasion be deemed
    a bar to or waiver of the same or any other right on any future occasion. The rights and remedies of the Payee shall be cumulative
    and may be pursued singly, successively, or together, in the sole discretion of the Payee.
	 	 
	6.	SUBORDINATION.
    The Maker’s obligations under this Promissory Note are subordinated to all indebtedness, if any, of Maker, to any unrelated
    third party lender to the extent such indebtedness is outstanding on the date of this Note and such subordination is required
    under the loan documents providing for such indebtedness.
	 	 
	7.	WAIVERS
    BY MAKER. All parties to this Note including Maker and any sureties, endorsers, and guarantors hereby waive protest, presentment,
    notice of dishonor, and notice of acceleration of maturity and agree to continue to remain bound for the payment of principal,
    interest and all other sums due under this Note notwithstanding any change or changes by way of release, surrender, exchange,
    modification or substitution of any security for this Note or by way of any extension or extensions of time for the payment
    of principal and interest; and all such parties waive all and every kind of notice of such change or changes and agree that
    the same may be made without notice or consent of any of them.
	 	 
	8.	GOVERNING
    LAW. This Note shall be governed by, and construed in accordance with, the laws of the State of Florida.
	 	 
	9.	SUCCESSORS.
    All of the foregoing is the promise of Maker and shall bind Maker and Maker’s successors, heirs and assigns; provided,
    however, that Maker may not assign any of its rights or delegate any of its obligations hereunder without the prior written
    consent of the holder of this Note.

 

IN
WITNESS WHEREOF, Maker has executed this Promissory Note as of the day and year first above written.

 

	NutraLife
    Biosciences, Inc. (Borrower)	 
	 	 	 
	By:	/s/ Edgar
    Ward	 
	Edgar
    Ward, Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]